GAS6 and metabolic dysfunction-associated steatohepatitis: This observation supports that the presence of steatosis alone is not sufficient to trigger the activation of the GAS6/TAM pathway and the release of sAXL, revealed to be an early biomarker of MASLD/MASH progression.